cvs caremark glp 1 recently announced that Wegovy will become the preferred GLP-1 medication for obesity treatment starting in July, leaving many questions for those currently prescribed Zepbound and other obesity medications. OAC is CVS Pharmacy® expands GLP-1 support

The study, published Monday in the journal Nature Medicine, is one of the first big-picture looks at the benefits and risks of these new drugs, which rapidly made an impact on health care, insurance coverage, the grocery industry, and even the economy of an entire country (Denmark, where Novo Nordisk, the maker of Ozempic and Wegovy is based.) These drugs have also been given partial credit for a recent dip in obesity rates in the US, which dropped in 2023 for the first time in over a decade

These agents act on vagal afferents, the hypothalamus, and the hindbrain, suppressing food intake and reducing body weight

Nutrients, 10 (2)

Please, please do not stop eating even if you arent hungry

Temperature control was handled correctly

Rapid weight loss from GLP-1 therapy can unmask or worsen existing kidney disease, necessitate blood-pressure or diuretic adjustment, and interact unpredictably with diabetes or cardiac medications